Limbic
+66%
est. 2Y upside i
Rank
#777
Sector
HealthTech
Est. Liquidity
~4Y
Data Quality
Data: MediumLimbic offers moderate expected upside of 66% over 2 years, but the analysis is clouded by missing growth data and a stale valuation mark.
Last updated: July 19, 2026
IF IPO window opens and category leadership recognized, exit multiple expands to 5x. Projected revenue of $34M yields $172M market cap (+175% after 20% dilution). High regulatory moat supports premium.
Exit multiple converges to public comp average of 3x. Revenue growth to $34M yields $103M market cap. 20% dilution reduces net upside to 65%.
Multiple compresses to 1.5x due to competitive pressure and market downturns. Revenue growth may slow. Preference stack at 44% of valuation wipes out most returns; net loss of 18%.
Preference Stack Risk
severeFunding Intensity
44%Total funding of $21.8M vs $50.1M valuation implies 44% overhang, requiring a ~1.44x exit just to clear preferences before common stock sees value.
Dilution Risk
highGiven cash burn and lack of profitability, a Series B raise within 18-24 months is likely, diluting existing holders by 20-30%.
Secondary Liquidity
noneNo secondary market activity detected; employee equity likely illiquid until exit.
Questions to Ask at the Interview
Strategic questions based on Limbic's data — designed to show you've done your homework.
- 1
“How does Limbic plan to achieve profitability with its current Gross Margin of 75% and what is the path to $100M ARR?”
- 2
“With the recent Nature Medicine study showing AI outperforming therapists, how does Limbic intend to commercialize this advantage and manage potential regulatory pushback?”
- 3
“Given the $14M Series A in 2024 and 44% preference overhang, what is the expected timeline and terms for the next funding round, and how would that affect employee equity dilution?”
Community
Valuation Sentiment
Our model estimates +66% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.